The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-11), Orion Oyj's 14-Day RSI is 95.26.
The industry rank for Orion Oyj's 14-Day RSI or its related term are showing as below:
ORINF's 14-Day RSI is ranked worse than 63.45% of 1048
companies
in the Drug Manufacturers industry
Industry Median: 47.88
vs ORINF: 95.26
Orion Oyj (OTCPK:ORINF) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Orion Oyj 14-Day RSI Related Terms
ORINF vs LLY, JNJ, ABBV: 14-Day RSI Comparison
For the Drug Manufacturers - General subindustry, Orion Oyj's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Oyj 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Orion Oyj's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Oyj (ORINF) has a 14-Day RSI of 95.26 as of Jul. 11, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Orion Oyj and its competitors. According to the industry distribution chart, Orion Oyj ranks #665 out of 1048 companies in the Drug Manufacturers industry, placing it in the top 63.5%.
Is Orion Oyj's 14-Day RSI too high?
Orion Oyj's current 14-Day RSI is 95.26. The Drug Manufacturers industry median 14-Day RSI is 47.88. Orion Oyj's value of 95.26 is 99% above this industry median. Based on the distribution chart, Orion Oyj ranks #665 out of 1048 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orion Oyj has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's 14-Day RSI compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #665 out of 1048 companies for 14-Day RSI. This places Orion Oyj in the lower half of its industry. The industry median 14-Day RSI is 47.88. Orion Oyj's value of 95.26 is 99% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 47.88, based on 1,048 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Oyj's current 14-Day RSI of 95.26 is 99% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Orion Oyj and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 47.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Oyj's current 14-Day RSI is 95.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Orion Oyj (ORINF) has a current 14-Day RSI of 95.26. The stock's GF Value™ is $80.88, compared to a current price of $82.75 — trading 2.3% above its estimated fair value. The current 14-Day RSI is 95.26 and 99% above the Drug Manufacturers industry median of 47.88. Orion Oyj's overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Orion Oyj (ORINF), the current 14-Day RSI is 95.26 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Oyj (ORINF) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Oyj stock appears to be overvalued.
The current stock price of $82.75 is trading 2.3% above its estimated GF Value™ of $80.88.
Key valuation signals for ORINF:
14-Day RSI: 95.26
GF Value™: $80.88 vs. price of $82.75 (2.3% above fair value)
Industry Position: 99% above the Drug Manufacturers median (#665 of 1048)
No single metric tells the full story. See the ORINF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
97GF Score
Get the complete analysis for ORINF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORINF has been successfully added to your 